Working with the US Food and Drug Administration to obtain approval of products under the Animal Rule

被引:14
作者
Park, Glen D. [1 ]
Mitchel, Jules T. [1 ]
机构
[1] Target Hlth Inc, 261 Madison Ave,24th Floor, New York, NY 10016 USA
来源
COUNTERMEASURES AGAINST CHEMICAL THREATS | 2016年 / 1374卷
关键词
Food and Drug Administration; Animal Rule; efficacy; safety;
D O I
10.1111/nyas.13126
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
While the development of medical products and approval by the U.S. Food and Drug Administration (FDA) is well known, the development of countermeasures against exposure to toxic levels of radiation, chemicals, and infectious agents requires special consideration, and there has been, to date, little experience in working with the FDA to obtain approval of these products. The FDA has published a regulation entitled "Approval of Biological Products when Human Efficacy Studies are not Ethical or Feasible." This regulation, known simply as the "Animal Rule," was designed to permit approval or licensing of drugs and biologics when efficacy studies in humans are not ethical or feasible. To date, 12 products have been approved under the Animal Rule. It is highly recommended that sponsors of products that are to be developed under the Animal Rule meet with the FDA and other government entities early in the development process to ensure that the efficacy and safety studies that are planned will meet the FDA's requirements for approval of the product.
引用
收藏
页码:10 / 16
页数:7
相关论文
共 5 条
[1]  
FDA, 2016, COMB PROD GUID DOC
[2]  
FDA, 2015, Product Development Under the Animal Rul e
[3]  
FDA, 2016, AN RUL INF
[4]  
FDA, 2007, Guidance for Industry and Review Staff Target Product Profile-A Strategic Development Process Tool
[5]  
[FDA Counter-Terrorism and Emergency Coordination Staff (CTECS)], 2014, COUNT TERR EM COORD